INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $8,489,000 | -27.6% | 127,927 | -13.2% | 0.40% | -15.9% |
| Q2 2019 | $11,729,000 | -13.2% | 147,409 | +22.0% | 0.47% | -14.4% |
| Q1 2019 | $13,515,000 | +42.3% | 120,820 | -25.7% | 0.55% | +50.3% |
| Q4 2017 | $9,497,000 | +2.1% | 162,560 | +89.9% | 0.37% | -7.8% |
| Q4 2016 | $9,301,000 | -25.7% | 85,603 | +12.5% | 0.40% | -28.7% |
| Q3 2016 | $12,522,000 | +65.7% | 76,079 | +43.7% | 0.56% | +53.0% |
| Q2 2016 | $7,555,000 | +33.2% | 52,950 | +20.0% | 0.36% | +31.9% |
| Q1 2016 | $5,671,000 | -22.1% | 44,139 | -9.4% | 0.28% | -19.8% |
| Q4 2015 | $7,280,000 | -36.8% | 48,742 | -29.8% | 0.34% | -42.8% |
| Q3 2015 | $11,510,000 | -29.4% | 69,398 | +2.8% | 0.60% | -22.7% |
| Q2 2015 | $16,294,000 | -10.6% | 67,504 | -1.0% | 0.78% | -15.0% |
| Q1 2015 | $18,217,000 | +73.2% | 68,180 | +1.1% | 0.91% | +63.8% |
| Q4 2014 | $10,517,000 | +443.5% | 67,415 | +724.4% | 0.56% | +385.2% |
| Q3 2014 | $1,935,000 | -67.4% | 8,177 | -67.4% | 0.12% | -65.7% |
| Q2 2014 | $5,942,000 | -33.5% | 25,113 | -7.4% | 0.34% | -33.4% |
| Q1 2014 | $8,942,000 | -10.4% | 27,113 | -81.5% | 0.50% | -6.9% |
| Q4 2013 | $9,980,000 | -14.7% | 146,167 | -13.8% | 0.54% | -18.3% |
| Q3 2013 | $11,704,000 | +430.8% | 169,543 | +244.8% | 0.66% | +393.3% |
| Q2 2013 | $2,205,000 | – | 49,175 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |